Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 12, 2019
Reporting Period: Single event date (September 12, 2019)
Business Context: The Company is an emerging growth company focused on cancer prevention and therapy. This filing discloses a material development regarding its intellectual property portfolio under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Intellectual Property Development: The United States Patent and Trademark Office (USPTO) issued a formal notice of allowance for Patent Application Serial No. 15/776,061.
Subject Matter: The patent is titled "CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR."
Program Impact: The patent covers the Company's INB03 Program, which utilizes dominant negative TNFα (DN-TNFα) technology for treating cancer.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the patent allowance but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Unusual Items: None reported in this filing.
Contingencies: The filing notes that the press release is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability incorporation.
Investor Verification Checklist
- Verify the status of Patent Application Serial No. 15/776,061 on the USPTO database to confirm the allowance and subsequent issuance.
- Review the full text of the Press Release (Exhibit 99.1) for details on the scope of the patent claims and potential commercial impact on the INB03 Program.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor future filings for the official issuance of the patent and any related regulatory milestones for the INB03 Program.